Login / Signup

Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety.

Iris K MinichmayrMats O KarlssonSiv Jonsson
Published in: Pharmaceutical research (2021)
The presented findings may help to avoid unfeasible trials and to rationalize the design of pharmacogenetic studies.
Keyphrases
  • clinical trial
  • open label
  • phase ii
  • double blind
  • phase iii